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Abstract 
Essential hypertension (EH) is a multi-factorial disorder and is the main risk factor for renal 
and cardiovascular complications. The research on the genetics of EH has been frustrated by 
the small predictive value of the discovered genetic variants. The HYPERGENES Project 
investigated associations between genetic variants and EH pursuing a two stage study by 
recruiting cases and controls from extensively characterized cohorts recruited over many 
years in different European regions.  
The discovery phase consisted of 1,865 cases and 1,750 controls genotyped with the 1 
Million SNPs Illumina array. Best hits were followed up in a validation panel of 1,385 
additional cases and 1,595 controls that were genotyped with a custom array of 14,055 SNPs. 
We identified a new hypertension susceptibility locus in the promoter region of endothelial 
Nitric Oxide Synthase (eNOS) gene, where rs3918226 shows strong association with EH 
(combined p-value = 2.58·10-13, OR = 1.54, 95% CI 1.37-1.73). A meta-analysis, using other in-
silico/de novo genotyping data for a total of 21714 subjects, resulted in an overall OR of 1.34 
(95% CI 1.25-1.44, p-value of 1.032·10-14). The quantitative analysis on a sample of 1820 
population-based individuals revealed an effect size of 1.91 (95% CI 0.16-3.66) for systolic BP 
and 1.40 (95% CI 0.25-2.55) for diastolic BP. We identified in-silico a potential binding site for 
transcription-factors of ETS family directly next to rs3918226, suggesting a potential 
modulation of eNOS expression.  
Solid biological evidence links eNOS with hypertension as it is a critical mediator of 
cardiovascular homeostasis and blood pressure control via vascular tone regulation. This 
new finding supports the hypothesis that there may be a causal genetic variation at this 
locus.
5 
 
Background 
Essential hypertension (EH) is a clinical condition affecting a large proportion (25-30%) of 
the adult population and is a major risk factor for cardiovascular and renal diseases [1,2]. It 
is a complex trait influenced by multiple susceptibility genes, environmental and lifestyle 
factors and their interactions. However, very little is known about the specific genetic 
components, and their complex interplay, that contribute to the final phenotype [3,4]. In 
the last years, huge efforts have been performed in recruiting and genotyping tens of 
thousands of individuals and meta-analysing dozens of cross-sectional population-based 
studies. In spite of this, the research on the genetics of EH has been frustrated by the small 
predictive value of the discovered genetic variants and by the fact that these variants 
explain a small proportion of the phenotypic variation [5,6,7,8,9,10]. EH is a late-onset 
disease and therefore the small discovered effect sizes could in part be due to the effect of 
misclassification, sample selection bias and inappropriate phenotyping of cases and controls 
[4,11,12]. The selection of cases and controls may have important effects on the results as 
misclassification bias can lead to loss of power. For common traits, such as EH, this bias can 
be remedied by defining more stringent selection criteria, by recruiting hyper-normal 
controls and adopting a more stringent case definition [11, 12].  
The HYPERGENES Project pursued a two-stage study to investigate novel genetic 
determinants of essential hypertension. Cases and controls were recruited from extensively 
characterized cohorts over many years in different European regions using standardized 
clinical ascertainment. Particular care was devoted to control selection. A large proportion 
of the sample has been followed for 5–10 years after DNA collection, allowing for the 
exclusion of controls that developed hypertension at a later age, thereby defining the hyper-
normal controls.  
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In summary, we identified rs3918226 in endothelial Nitric Oxide Synthase (eNOS) gene 
associated to essential hypertension at genome wide significance level and 7 more SNPs in 
eNOS showing significant association. rs3918226 has been validated in the two-stage study 
and in-silico replicated in different samples. 
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Methods   
Study Population 
Cases and controls were recruited from extensively characterized cohorts using 
standardized clinical ascertainment and collected over many years in different European 
regions. Cases and controls were balanced within each population group (North Europe, 
Continental Italy and Sardinia). We defined cases as having developed hypertension (Systolic 
Blood Pressure (SBP)>140 mmHg and Diastolic Blood Pressure (DBP)>90 mmHg) or started 
antihypertensive treatment before the age of 50. Individuals with secondary hypertension 
(high blood pressure resulting from another condition such as kidney or adrenal disease) 
were excluded (suppl. Methods S1). Controls were selected to have remained within 
normotensive blood pressure range (SBP<135 and DBP<85 mmHg) until at least the age of 
55. Moreover, a large proportion of the sample has a follow-up of 5–10 years after DNA 
extraction, allowing for the exclusion of controls that developed hypertension at a later age 
(supplemental Methods S1).  
In order to perform a genetic association with continuous BP phenotypes, we considered 
two additional cohorts of the HYPERGENES Consortium (FLEMENGHO-EPOGH, n=1514 and 
WHSS, n=306, see supplemental methods S2) that provided population-based data for 
subjects 40-60 years old. 
Description of the different samples is reported in the supplemental methods S2. 
Institutional review boards at each collection site approved the study and all individuals 
gave their informed consent. A further Ethical Revision of the University of Milano and of 
the HYPERGENES Internal Ethical Steering Board approved the entire process. 
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Genotyping and Imputation 
Genotyping details are shown in the Data Supplement (supplemental methods S3-S6). 
Briefly, in the Discovery phase, 4059 samples were genotyped using the Illumina 1M-duo 
array. Imputation was performed using MACH [13] using as reference the 1000 Genomes 
haplotypes (release June 2010) (supplemental method S3).  
To retest and fine map the genes found associated with EH in discovery phase an Illumina 
custom chip of 14055 markers was created starting from a list of best-associated SNPs in the 
discovery phase (p-value <1·10-4) and a list of candidate SNPs based on a priori biological 
knowledge. Additional SNPs neighboring the best and candidate SNPs were selected from 
the Illumina Gene Annotation of 1M duo and 1M quad chips. Filters for Minor Allele 
Frequency (MAF) and p-value were applied and all SNPs mapping within 100kb upstream 
and downstream of each selected gene were included. This gave a list of 9669 Best SNPs and 
4,386 Candidate SNPs, totaling 14055 SNPs (supplemental methods S4). In the validation 
stage, additional 2869 samples were genotyped using the Illumina Custom chip. After 
genotyping, all SNPs on custom chip were visually inspected in order to check the accuracy 
of the cluster plots (supplemental method S5).  
For the replication stage, we used the in-silico data of rs3918226 from ASCOT/AIBIII/NBS, 
BRIGHT, EPIC Turin, HYPEST and NORDIL/MDC studies. In particular, ASCOT/AIBIII/NBS, 
BRIGHT and NORDIL/MDC samples were genotyped with Illumina Human CVD BeadArray. 
HYPEST samples were directly re-genotyped using the KASPAr assay at Barts and The London 
Genome Centre. SNP rs3918226 was genotyped in EPIC Turin cohort by the 5’-Nuclease 
assay (TaqMan) with a fluorogenic Minor Groove Binder probe on ABI-7900 (Applied 
Biosystems) (supplemental methods S6).  
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Statistical analysis 
All statistical analyses were performed in accordance with the protocol written by C.A 
Anderson et al [14] (supplemental methods S7, S8 and S9). We assessed population 
stratification within the data using principal components analysis (PCA) as implemented in 
EIGENSTRAT [15,16] to infer continuous axes of genetic variation. In the Discovery phase, we 
tested each SNP for association with hypertension using a logistic regression under an 
additive model with adjustment for sex and for the first 10 PCs, as implemented in PLINK 
[17]. Residual inflation (lambda inflation factor = 1.04) of the test statistic was corrected 
using genomic control. After association tests the cluster plots of all SNPs taken forward for 
validation were manually inspected to check the fidelity of genotype assignment. In the 
Validation phase, logistic regression analysis was carried out using an additive genetic model 
adjusted for sex and for the first 10 PCs. The basic statistical analyses were performed in 
accordance with the protocol written by G.M. Clarke et al [18].  
Combined analysis for HYPERGENES Discovery, HYPERGENES Validation, ASCOT/AIBIII/NBS, 
BRIGHT, Epic Turin, HYPEST and NORDIL/MDC results was conducted using both Z-score and 
inverse variance weighting meta-analysis as implemented in METAL [19]. In the meta-
analysis, a threshold of 5·10–8 was considered significant at genome-wide level after 
correction for multiple testing. 
Moreover, we tested for multiplicative interaction between the discovered eNOS SNP 
(rs3918226) and the most plausible interactive partners of eNOS gene: actin genes (ACTA1, 
ACTA2, ACTB, ACTG1, ACTG2) and Heat Shock Protein-90 genes (HSP90AA1, HSP90AA2, 
HSP90AB1). In total 159 SNPs were tested for interaction. Sex and ancestry principal 
components were included as covariates in the logistic regression. To assess significance, 
multiple testing corrections were applied. Since many of the SNPs are in high LD with each 
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other, we permuted the phenotype 500 times to control the false discovery rate. We used a 
loose 20% false discovery rate threshold providing suggestive evidence for interactions. 
The quantitative effect of rs3918226 has been tested on two additional population-based 
cohorts from the HYPERGENES consortium (EPOGH-FLEMENGO and WHSS, see 
supplemental methods S2). For individuals taking antihypertensive medication, we added 15 
and 10 mmHg to the measured SBP and DBP, respectively, to account for treatment [20,6]. 
SBP and DBP were adjusted for sex, age, age2 and body mass index.  
 
Recognition sequences for transcription factors 
The recognition sequences for transcription factors (TFs) in eNOS region were searched with 
the PATCH algorithm of TRANSFAC [21,22]. The TRANSFAC database on eukaryotic 
transcriptional regulation includes data on transcription factors, their target genes and 
regulatory binding sites. Potential binding sites for TFs within the region of interest were 
also searched using the TFSEARCH database with a cutoff score of 85 [ 23 ].
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Results 
A classical two-stage case-control strategy was employed with a discovery phase of 1,865 
cases and 1,750 controls (2,294 males, 1,321 females) all genotyped on the Illumina 1M Duo 
chip. The sample consisted of an ethnically diverse population (25.06% North Europeans, 
38.70 % Sardinians and 36.24% Continental Italy subjects). The discovery phase was 
followed by a validation phase of an additional 1,385 cases and 1,595 controls (1,417 males 
and 1,214 females). According to ethnicity, the validation sample was comprised of 1262 
North Europeans (47.97%), 788 Sardinians (29.95 %) and 581 Continental Italians (22.08%). 
Supplemental tables S1 and S2 show the demographic characteristics and baseline 
measures. 
Principal Component Analysis (PCA) of the genotype data was carried out to find the major 
axes of variation used as covariates to correct for population stratification [24]. The 
discovery samples in the principal component map showed three (roughly) equal-sized 
distinct clusters corresponding to the three main ethnic groups, as expected from the study 
design (supplemental figure S1). All association analyses were adjusted for the ancestry 
principal components by including them as covariates in the logistic regression model. In 
addition genomic control (GC) correction was applied (since genomic inflation factor was 
1.04). In the discovery phase, 90 SNPs (57% intragenic) with p-value < 1·10-4 were identified 
after GC (supplemental figure S2, supplemental table S4). The most promising SNPs were 
genotyped in the validation samples using an Illumina Infinium Custom chip. The meta 
analysis of the discovery and validation data revealed SNP rs3918226 to be associated with 
EH in Caucasians, reaching a Pcombined of 2.58·10
-13 and OR of 1.54 per T allele (95% CI, 1.37-
1.73) under an additive model (figure 1, table 1 and supplemental figure S4). Estimated 
odds ratios in the Discovery and Validation samples were consistent across the different 
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Caucasian populations of the HYPERGENES sample (supplemental figure S5).  
The polymorphism rs3918226 maps to the promoter region of the eNOS gene (-665 C>T, 
NOS3) [25,26]. The T allele frequencies in the present study are 13.8% in cases and 8.9% in 
controls. SNP rs3918226 is monomorphic in the non-Caucasian HYPERGENES samples 
(Wandsworth Heart & Stroke Study cohort, WHSS) and African and Asian HapMap samples. 
The second best hit (G/A SNP, MAF of A allele= 3%) with P value 2.46·10-6 and OR 2.25 (at 
position 150,314,954) was imputed based on the 1000 Genomes haplotypes (release June 
2010), its imputation quality was very high (r2-hat = 0.94). Further 7 SNPs within eNOS gene 
showed significant p-values (1·10-3 < p-values < 1·10-5): rs2853792 (intronic, Pcombined = 7.76 
·10-5), rs1549758 (coding, Pcombined =  3.32 ·10
-4), rs1800779 (intronic, Pcombined =  1.16 ·10
-3), 
rs6951150 (intergenic, Pcombined = 1.64 ·10
-3), rs743507 (intronic, Pcombined = 1.76 ·10
-3), 
rs1800780 (intronic, Pcombined = 1.96 ·10
-3), rs1800783 (intronic, Pcombined = 2.89 ·10
-3) (figure 
1). Table 1 shows also other significant SNPs with p-values between 1·10-3 and 1·10-5 
mapping different genes as calcium-activated potassium channel subunit alpha-1 (KCNMA1), 
plasminogen (PLG), retinoid-related orphan receptor alpha (RORA) and WW domain-
containing protein 1 (WWC1). 
Moreover, the signals of SNPs previously presented in literature are in our study in the same 
direction as the original studies [6,7,8] showing evidence of a marginally significant 
association in HYPERGENES (supplemental table S5). 
We meta-analyzed rs3918226 using in silico data from ASCOT/AIBIII/NBS, BRIGHT, EPIC-Turin, 
HYPEST and NORDIL/MDC samples (methods S2, S6) resulting in an overall OR of 1.34 per T 
allele (95% CI 1.25-1.44, Pcombined = 1.032·10
-14) (table 2 and figure 2) for a total of 21714 
subjects. Since case and control definitions differed between HYPERGENES (discovery and 
validation) and the in-silico replication samples, the ORs are not directly comparable. In our 
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study, the p value of heterogeneity calculated for HYPERGENES samples is 0.13. It decreased 
slightly, but remained non-significant, as expected, when also EPIC-Turin was considered 
together in the meta-analysis (p=0.092) since the recruitment criteria for cases and controls 
were identical. Conversely, the heterogeneity increased significantly (p=0.005) when 
HYPERGENES samples were meta-analyzed with all the other samples (ASCOT/AIBIII/NBS, 
BRIGHT, HYPEST and NORDIL/MDC).  
Moreover we tested for epistatic multiplicative interactions between eNOS rs3918226 and 
all available polymorphisms in genes known to be involved in targeting and regulating the 
overall availability of eNOS at the cell membrane [27, 28,29]: actin genes (ACTA1, ACTA2, 
ACTB, ACTG1, ACTG2) [30,31] and HSP90 genes (HSP90AA1, HSP90AA2, HSP90AB1) [27]. 
Nominally significant interactions were observed between rs3918226 and rs13447427 (p-
value =1.34·10-3) in actin beta gene (ACTB), rs7503750 (p-value =1.57·10-3) in actin gamma 1 
(ACTG1) and rs4922796 and rs17309979 (p-value =3.47·10-3, p-value =4.88·10-3) in heat shock 
protein alpha 2 (HSP90AA2) (supplemental table S6). When controlling for multiple testing 
these interactions remained significant at a False Discovery Rate of 20%.  
The quantitative analysis confirmed the qualitative observation. In fact, the  coefficient 
of the regression between SBP or DBP with rs3918226 is respectively 1.91 (95% CI 0.16-3.66) 
and 1.38 (95% CI 0.25-2.55) per T allele. The coefficient is the effect size on blood pressure in 
mm Hg per coded allele based on an additive genetic model. The BP distribution according 
to rs3918226 genotype is shown in supplemental table S7.  
Since rs3918226 maps to the promoter region of eNOS, we tested whether it may fall into a 
regulatory binding site. Using the PATCH algorithm of TRANSFAC database [21] we 
characterized a putative binding site for transcription-factors of ETS family directly next to 
rs3918226. The ETS family members are present in endothelial cells and participated in 
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activation of the eNOS promoter [32]. Using the TFSEARCH tool [23] we confirmed this 
finding with a score of 87.3.  
We also tested the degree of evolutionary conservation of rs3918226 locus in primates and 
placental mammals using the conservation track of UCSC genome browser. Supplementary 
figure S6 shows that the region in which rs3918226 lies is conserved from placental 
mammals to primates. 
.  
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Discussion 
Essential hypertension (EH) is a complex clinical condition representing the main risk factor 
responsible for renal and cardiovascular complications. The HYPERGENES Project 
investigated undiscovered associations between genetic variants and EH pursuing a two 
stage study by recruiting cases and controls from extensively characterized cohorts 
recruited over many years in different European regions.  
We discovered a SNP in the promoter region of the eNOS gene (endothelial nitric oxide 
synthase) to be significantly associated with hypertension (OR, 1.54; 95% CI, 1.37 to 1.73; p-
value = 2.58·10-13).  
The result was confirmed by meta-analyzing in-silico data from ASCOT/AIBIII/NBS, BRIGHT, 
EPIC-Turin, HYPEST and NORDIL/MDC samples for a total of 21714 subjects (OR, 1.34; 95% CI 
1.25-1.44; p-value = 1.032·10-14). We observed heterogeneity in the findings of meta-analysis 
(p=0.005 for Q-test of heterogeneity) that could be due to both different sample sizes and 
recruitment criteria not directly comparable between HYPERGENES and the in-silico 
replication samples (figure 2).  
The quantitative effect of rs3918226 was also estimated in continuous BP phenotypes, 
resulting in a  coefficient of 1.96 for SBP and 1.40 for DBP, despite the low p-values of the 
regression probably due to the low sample size. This finding reinforces the observation on 
the qualitative phenotype. 
The use of the Illumina 1M array and Human CVD BeadArray was crucial in detecting the 
association since rs3918226 is not present on other commercial arrays [33]. Furthermore the 
region is poorly covered by other genotyping platforms as a relatively high recombination 
rate towards the coding region (figure 1) has resulted in low linkage disequilibrium (LD) with 
markers present on older platforms (e.g. rsq-hat < 0.2 for Affy500K platform). These facts 
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largely limited the potential to replicate our finding using data from other GWAS samples, 
almost all of which relied on older platforms.  
In the combined analysis, we found other SNPs mapping different genes as KCNMA1, PLG, 
RORA and WWC1 (table1) with p-values ranging from 1·10-3 and 1·10-5.  
We propose rs3918226 as a novel susceptibility SNP since it has been never described 
previously as associated to hypertension in a genome scan. Moreover, independently on the 
p-values (expected to be relatively small, considering the small sample size) we confirmed in 
the present project the effect size of most top SNPs described in the previous studies [6,7,8] 
(supplemental table S5).  
We identified a potential transcription-factor binding site for the ETS-family domain directly 
next to rs3918226. The members of ETS family, as ETS-1 and ELF-1, are essential factors for 
the activation of eNOS promoter [32]. This suggests that, by affecting transcription factor-
binding affinity, rs3918226 might modulate the transcription of eNOS gene. It is also worth 
noting that the region in which rs3918226 lies is conserved from placental mammals to 
primates.  
There is considerable biological evidence linking eNOS with hypertension and hypertension-
associated cardiovascular target organ damage [34]. eNOS, which catalyses the synthesis of 
nitric oxide (NO) by vascular endothelium, is responsible for the vasodilator tone that is 
fundamental for the regulation of blood pressure. Furthermore, eNOS is a critical mediator 
of cardiovascular homeostasis through regulation of blood vessels diameter and of the 
maintenance of an anti-proliferative and anti-apoptotic environment. 
As NO is highly active, it cannot be stored inside producing cells. Indeed, eNOS signalling 
capacity must be controlled, at least in part, by regulating its targeting from Golgi apparatus 
to plasma membrane, by its compartmentalization within the plasma membrane and by its 
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later internalization from the plasma membrane to the cytoplasm. eNOS is a dually acylated 
peripheral membrane protein that is targeted to endothelial plasmalemmal caveolae 
through an interaction with the caveolae structural protein, Caveolin-1 (Cav1)[ 27,28]. Cav1 
inhibition of eNOS is lessened by Calmodulin (Calm) causing dissociation of eNOS from 
Caveolin. This regulatory mechanism is further altered by Heat Shock Protein-90 (HSP90) 
[28] which binds to eNOS and facilitates displacement of Cav1 by Calm. Moreover, eNOS 
directly interacts with actin cytoskeleton [30]. Recently, Kondrikov added that beta-actin is 
associated with eNOS oxygenase domain increasing eNOS activity and NO production [31]. 
To explore such pathway we tested the interaction between the discovered eNOS SNP and 
its most plausible interactive partners. We observed nominally significant interactions 
between rs3918226 and rs13447427 in actin beta (ACTB), rs7503750 in actin gamma 1 
(ACTG1) and rs4922796 and rs17309979 in Heat Shock Protein-90 alpha 2 (HSP90AA2) gene. 
In conclusion, with a stringent case-control design and a population based study, we 
identified a novel hypertension susceptibility locus in the promoter region of eNOS with a 
relatively high effect size. Our finding could provide new insights into the mechanism of 
vascular regulation and could help in better understanding the genetics of EH. Furthermore, 
we believe that this indication can be useful to guide fine-mapping or sequencing efforts to 
single out causal variants.  
Perspectives 
Further investigations and high-throughput sequencing of region of interest will help to 
identify the real causal variant and to clarify the functional role of eNOS in essential 
hypertension. 
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Figure Legend 
Figure 1: Local Manhattan plot for the NOS3 (endothelial NOS) region. Each circle 
represents a SNP, its y-coordinate is the -log10 association P value for hypertension, 
the x-coordinate represents the physical position on the chromosome (on build 36). 
When replication data was available the combined P value was used, otherwise the 
discovery P value. Circles are filled with different shades of red according to the LD 
(r2) between the given SNP and the lead SNP (rs3918266, green circle). Blue line 
indicates the recombination rate. The second best hit with P value 2.46E-6 (at 
position 150,314,954) was imputed based on the 1000 Genomes haplotypes 
(release June 2010), its imputation quality was very high (r2-hat = 0.94). 
 
Figure 2: Forest plot of meta-analysis between Hypergenes Discovery, Hypergenes 
Validation, ASCOT/AIBIII/NBS, BRIGHT, EPIC Turin, HYPEST and NORDIL/MDC 
studies. The squares and the horizontal lines correspond to the OR and 95% CI of 
each study, the size of squares is proportional to weights (also shown as 
percentage), the dotted red line and the diamond represent the overall combined 
OR and 95% CI. 
 Marker 
Name 
Chr Position 
Effect 
allele 
Other 
allele 
Gene 
Minor Allele 
Frequency 
(Discovery) 
OR 
(Discovery) 
P 
(Discovery) 
Minor Allele 
Frequency 
(Validation) 
OR 
(Validation) 
P 
(Validation) 
OR 
(combined) 
CI (combined) 
Inverse 
variance 
weighted P 
(combined) 
Z-score P 
(combined) 
rs3918226 7 150321109 T C NOS3 0.116 1.425 4.81E-06 0.1148 1.71 2.55E-09 1.538 [1.372-1.726] 1.98E-13 2.58E-13 
rs341408 15 58928982 G A RORA 0.3799 0.786 1.74E-06 0.3871 0.956 4.29E-01 0.856 
[0.7949-
0.9219] 3.98E-05 2.79E-05 
rs4976593 5 167710021 G A WWC1 0.3278 1.27 3.75E-06 0.3394 1.045 4.60E-01 1.169 
[1.0826-
1.2622] 6.64E-05 5.29E-05 
rs631208 16 9307225 G A RP11-473I1.1 0.4068 0.798 8.09E-06 0.4173 0.951 3.84E-01 0.862 
[0.8001-
0.9284] 8.89E-05 6.36E-05 
rs7907270 10 78550949 G A KCNMA1 0.401 1.27 2.35E-06 0.4048 0.989 8.53E-01 1.141 
[1.0585-
1.2301] 5.75E-04 4.25E-04 
rs10519080 15 58925751 G A RORA 0.1412 1.369 5.79E-06 0.1385 0.979 7.95E-01 1.187 
[1.0710-
1.3158] 1.09E-03 8.49E-04 
rs1406891 6 161107070 G A PLG 0.4853 1.251 3.99E-06 0.4563 0.949 3.50E-01 1.112 
[1.0348-
1.1953] 3.87E-03 2.97E-03 
rs783182 6 161088538 G A PLG 0.4892 0.797 2.95E-06 0.4857 1.068 2.42E-01 0.902 
[0.8395-
0.9700] 5.31E-03 4.15E-03 
rs1084656 6 161101282 C A PLG 0.4996 1.243 6.67E-06 0.4757 0.936 2.39E-01 1.103 
[1.0264-
1.1859] 7.66E-03 6.35E-03 
rs783145 6 161072439 G A PLG 0.4989 0.788 8.53E-07 0.4724 1.102 8.45E-02 0.909 
[0.8459-
0.9767] 9.27E-03 6.85E-03 
rs1247558 6 161110189 G A PLG 0.4982 1.24 8.30E-06 0.4774 0.932 2.14E-01 1.1 
[1.0237-
1.1827] 9.42E-03 7.93E-03 
 
 
Table 1. Meta-analysis results for the top SNPS in the HYPERGENES study. The table shows association results (OR and p-values) for Discovery 
and for Validation samples, and for the combined analysis (both inverse variance weighting and Z-score meta-analysis). P values and ORs with 
the associated 95% CI have been calculated under an additive model using logistic regression adjusted for gender and PCs. To retrieve 
information about SNPs and their genomic context (the nearest gene) we used the hg18 (NCBI 36) assembly. 
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Figure 1. Local Manhattan plot for the NOS3 (endothelial NOS) region. 
 
 
 
 
22 
 
 
 Study Sample Size OR SE 95% CI P-value 
       
Hypergenes 
Samples 
HYPERGENES_DISCOVERY 3596 1.43 0.11 1.224-1.657 4.81E-06 
HYPERGENES_VALIDATION 2610 1.71 0.155 1.440-2.049 2.55E-09 
Combined Analysis HYPERGENES 6206 1.54 0.038 1.372-1.726 2.58E-13 
              
Replication 
Samples 
 
  
ASCOT_AIBIII_NBS 4049 1.06 0.092 0.895-1.256 4.97E-01 
BRIGHT 3641 1.39 0.126 1.168-1.663 2.32E-04 
EPIC Turin 2714 1.28 0.126 1.050-1.551 1.44E-02 
HYPEST 1204 1.13 0.236 0.754-1.705 5.45E-01 
NORDIL_MDC 3900 1.25 0.124 1.030-1.519 2.40E-02 
Combined Analysis of Replication Samples 15508 1.23 0.056 1.125-1.344 6.50E-06 
            
              
       
  Sample Size OR (combined) 
95% CI 
(combined) Combined P  (Z-score) 
Combined P  (Inverse variance 
weighted) 
       
 META-ANALYSIS 21714 1.34 1.248-1.437 1.032E-14 6.198E-16 
              
 
Table 2. In silico meta-analysis results for rs3918226 (T/C, effect allele/other allele). Top: association results (Odds Ratios, Standard Errors, 
Confidence intervals and p-values) for Discovery, Validation and combined analysis of the HYPERGENES samples. Middle: results for 
ASCOT/AIBIII/NBS, BRIGHT, Epic Turin, HYPEST and NORDIL/MDC studies and combined analysis of replication in silico samples. Bottom: Meta-
analysis results for all samples using both the z-score and inverse variance weighted p-value methods. 
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Figure 2. Forest plot of meta-analysis between Hypergenes Discovery, Hypergenes Validation, ASCOT/AIBIII/NBS, BRIGHT, EPIC Turin, HYPEST 
and NORDIL/MDC studies. 
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Supplemental Methods S1: Inclusion Criteria 
Definition of case: 
A participant could be included as hypertensive case if he/she could self report to be of Caucasian 
Origin, was unrelated with other participants, had diastolic blood pressure (DBP) > 90 mmHg and 
systolic blood pressure (SPB) > 140 mmHg or under antihypertensive treatment before the age of 50. 
Definition of control: 
A participant could be included as normotensive if he/she could self report to be of Caucasian Origin, 
was unrelated with other participants, had DBP <85 mmHg and SBP <135 at least until 55 years of age 
and had never been treated for hypertension. 
All hypertensive and normotensive subjects were otherwise healthy, non obese (body mass index < 
30), non dyslipidemic (serum cholesterol <250; serum triglycerides <200 mg/dl - values obtained at 
screening prior inclusion in the study) and had no abnormal findings on physical examination. 
A large proportion of the sample has been followed for many years after DNA collection, allowing for 
the exclusion of controls that developed hypertension at a later age. In particular the FLEMENGHO-
EPOGH cohorts have been followed from 2 to 10 years and the Milan Cohorts from 5 to 15 years. 
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Supplemental Methods S2: HYPERGENES Consortium 
Data presented here are part of data generated within the HYPERGENES Project, an EU supported IP, 
under FP7 (http://www.hypergenes.eu), aimed at the definition of a comprehensive genetic-
epidemiological model of essential hypertension and of the intermediate phenotypes of 
hypertension, specifically associated Target Organ Damage (TOD). 
 
Cohorts contributing to the discovery sample: 
 The FLEMENGHO (Flemish Study on Environment, Genes and Health Outcomes) - EPOGH 
(European Project on Genes in Hypertension) cohort has been the first large- scale study on 
genetic epidemiology of blood pressure and associated phenotypes in Europe and has already 
produced 35 scientific papers. It recruited family-based random samples in 5 eastern and 2 
western European countries [1,2]. Overall the cohort available for HYPERGENES totals 4889 
individuals (~13% hypertensive). According to our "macro-region concept, the 
FLEMENGHO/EPOGH cohort is considered a "North-European" cohort. From FLEMENGO-EPOGH 
cohort, 248 cases and 275 controls were genotyped in the discovery sample.  
 The IMMIDIET study is a population-based cross-sectional study, funded by the European Union 
(FP5) [3]. It compares healthy couples from regions of England, Belgium and Italy in order to 
evaluate the present dietary habits and the risk profile of the three communities at different risk 
of myocardial infarction. A large body of clinical (mostly cardiovascular) and environmental data 
are available. In the discovery phase, 106 controls and 163 cases were recruited and genotyped. 
 Milano and Sassari cohorts (Italian and Sardinian cohorts) have been collected with a different 
target, since the focus was more directed on the pathophysiology on EH and TOD. For this reason, 
in most hypertensives, the phenotypes were collected before any pharmacological treatment was 
started [4]. The specificity of the cohorts is in the possibility of providing results for 2 important 
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secondary outcome analyses. In fact, while today there is no substantial difference in shared 
environment between North Sardinia and Milano, there is no doubt that substantial genetic 
difference exists [5] and supplemental figure S1]. Overall the Italian cohort available for 
HYPERGENES totals 1544 individuals (~52% hypertensives) while Sardinian cohort totals 1599 
(~53% hypertensives). 
 The cohort of the Wandsworth Heart & Stroke Study (WHSS) [6] has the characteristic of being a 
multiethnic community-based study, drawn from the same geographical area of South London. 
The sample totals 1577 individuals (~40% hypertensives), evenly distributed for ethnic origin; 33% 
Caucasians, 33% of African descent, 33% of South Asian descent. The population has been 
extensively phenotyped. Mortality follow-up through death certificates and cancer registrations 
are available. It is a unique multiethnic cohort sharing the same urban environment. Seventy eight 
cases and forty six controls with Caucasian origin were included in the discovery phase. 
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Cohorts contributing to the Validation sample 
Additional samples were received from the major contributing units: 
 Milano (Continental Italy). In the validation phase, 318 controls and 250 cases were recruited. 
 Paris (France):  The French hypertensive patients were selected from the HYPERGENES dataset of 
hypertensive families consecutively recruited in Paris, since 1990 [7]. The dataset comprises more 
than 1000 index cases and more than 500 hypertensive siblings. In this study, only the 958 
subjects (604 hypertensives and 354 normotensives) filling the criteria for inclusion in the 
HYPERGENES study with DNA available were included. Three hundred fifty four French 
normotensive patients were selected by the Institute Regional pour la Santé (IRSA, Pr J Tichet) 
during an annual medical visit of preventive medicine. All of the them were Caucasians, 
normotensive after 50 years of age and had no history of diabetes mellitus and were recruited in 
three main centers of the regions Centre and Picardie which are located about 200 kms South 
and North of Paris, respectively. These controls were previously used in other case control studies 
made by the Paris group [8]. 
 PROGRESS cohort. The “Perindopril protection against recurrent stroke study” (PROGRESS) was 
designed to determine the effects of a blood-pressure-lowering regimen in hypertensive and non-
hypertensive patients with a history of stroke or transient ischemic attack [9]. In the validation 
phase, we genotyped 281 subjects divided between 119 affected and 162 normotensives. 
 Sassari (Sardinia). Eight hundred and thirty one samples (47% hypertensives) were included as 
validation samples. 
 VFHS (Victorian Family Heart Study), a general population study of 2959 individuals [10]. Only 
213 unrelated subjects satisfying the criteria for inclusion as controls in the HYPERGENES study 
were included. 
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Cohorts contributing to the replication stage  
 ASCOT/AIBIII/NBS: The cases (BP of >160/100mmHg untreated or >140/90mmHg treated and >40 
years + other risk factors) were derived from the UK/Irish participants of the Anglo-Scandinavian 
Cardiac Outcomes Trial (ASCOT) [11]. The normotensives were derived from two resources: NBS 
study and AIBIII study (Irish controls). The total sample is composed of 4049 subjects.  
 BRIGHT study (The BRItish Genetics of HyperTension) [12] : the inclusion criteria for the 
hypertensives were a diagnosis of hypertension prior to 50 years, and BP ≥ 150/100mmHg for a 
single reading or ≥ 145/95mmHg for 3 consecutive readings. Exclusion criteria included BMI>35, 
diabetes, secondary hypertension or a co-existing illness. Normotensives had SBP ≤140mmHg and 
DBP≤ 90mmHg and were not taking any anti-hypertensive medications, the controls were 
recruited from similar geographical regions to the cases. A total of 3641 individuals were included 
in these analyses. 
 EPIC Turin study is a longitudinal cohort of 10,603 volunteers, aged 35-64 years at baseline, from 
the Turin area, Italy. Blood pressure was measured using a mercury sphygmomanometer, in seated 
position, on the left arm. Full details of the cohort are reported elsewhere [13]. Only 2714 
individuals were considered here, to apply HYPERGENES selection criteria.  
 HYPEST (HYPertension in ESTonia) [14]: cases were selected based on the clinical diagnosis and 
profile of blood pressure specialists during the patients’ ambulatory visits or hospitalization at the 
North Estonia Medical Center, Centre of Cardiology, or at the Cardiology Clinic, Tartu University 
Hospital, Estonia. The controls were recruited from long-term blood donors. The total sample 
used in the current study is comprised of 1204 individuals.  
 NORDIL/MDC: The cases were selected from the Nordic Diltiazem (NORDIL) study [15]. 
Hypertensives were defined as having at least two consecutive BP measurements greater than 
160mmHg SBP and 100mmHg DBP, with the diagnosis made before age 63 years. The controls 
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were identified from the Malmö Diet and Cancer study (MDC) [16]. These individuals had to have 
a SBP < 120mmHg and DBP < 80mmHg and were at least 50 years of age and free from 
cardiovascular events (coronary events and stroke) during 10 years of follow up and not on any 
antihypertensive medication. The total sample is made up of 3900 cases and controls. 
 
Population-based cohorts contributing to the quantitative analysis on SBP and DBP 
In order to estimate the effect of continuous BP phenotypes, we considered two cohorts of the 
HYPERGENES Consortium that had also collected a population-based sample. We then assumed a 
normal linear regression model for SBP and DBP.  
For individuals taking antihypertensive medication, we added 15 and 10 mmHg to the measured SBP 
and DBP, respectively, to account for treatment [17,29]. SBP and DBP were adjusted for sex, age, age2 
and body mass index. 
 EPOGH-FLEMENGO sample: we considered a random sample of 1514 subjects with an age 
between 40 and 60 years (supplemental table S3).  
 WHSS random population sample: we considered a random sample of 306 Caucasians subjects 
with an age between 40 and 60 years for the random population study. Besides Caucasians, we 
also genotyped 254 black Caribbean, 141 black Africans and 407 South Asians for a total of 1132 
subjects. The eNOS SNP is very rare in non-Caucasians; in this dataset the T allele of rs3918226 
had frequency of 0.75% (supplemental table S3). 
 
Supplemental Methods S3: Genotyping and data filtering in the discovery 
DNA was extracted from peripheral blood with standard procedures. 
In the discovery phase all samples were genotyped using the Illumina 1M-duo arrays (Illumina Inc, San 
Diego, CA, USA). The chip captures 1199187 SNPs. In addition to markers necessary for broad genome 
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coverage the chip contains 21877 non- synonymous SNPs, 51207 SNPs in sex chromosomes, 138 in 
mitochondrial DNA, 35969 SNPs covering recently reported copy number variant regions, 30908 SNPs 
in MHC and ADME regions. 
Genotyping was performed in two different genotyping centres: Milan University (UNIMI) and 
Lausanne University (UNIL). UNIMI genotyped 2064 subjects (1270 controls and 794 cases) whereas 
UNIL performed the genotyping of 1995 subjects (665 controls and 1330 cases). 
All raw intensity data were collected in UNIMI genotyping centre and analysed with the Illumina 
Software Genome Studio for genotype calling, using the Illumina reference cluster file. A DNA call rate 
threshold was set at 0.95 and DNAs with call rate ≤ 0.95 were excluded from the final data set. For 
each DNA, data from X chromosome were used to check for discordance with ascertained sex. 
After association analysis, a final assessment of genotype quality was performed for the significantly 
associated SNPs (p-value<1·10-4) with visual inspection of cluster plots. 
As genotyping was performed in two Laboratories, replications were designed in order to estimate the 
genotyping error rate between the two Genotyping Centres. DNAs from 20 individuals were 
genotyped with the 1M-duo Illumina's BeadChips. 
Within samples with Call Rates >0.95, 99.624% of the genotype calls were concordant and 0.376% 
were discordant. 
A cross-check between the scan performances of the two Illumina iScan platforms was also 
performed. Ten chips (20 samples) were processed and scanned in UNIMI (average DNA call rate 
0.994). The same chips were re-scanned in UNIL. We could demonstrate that 99.189% of the calls 
were concordant and 0.0053% was discordant between the two platforms. For 0.805% of the calls we 
could not do the comparison since this percentage accounts for calls available in the chip scanned in 
one Lab but not in the other and vice-versa. 
Imputation was performed using MACH [18] using as reference the 1000 Genomes haplotypes 
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(release June 2010). Measured SNPs with >90% call rate, minor allele frequency >1%, and Hardy–
Weinberg p-value >1·10-7 were included as input set. In subsequent analysis imputed SNPs with low 
imputation quality (r2-hat<0.3 or MAF<1%) were ignored. Whenever the measured genotype was 
available, it replaced the imputed value. 
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Supplemental Methods S4: Assembly of the Custom chip 
In order to retest and fine map the genes found associated whit EH we selected about 15000 SNPs for 
a custom iSelect HD Illumina. 
The selection was based on: 
1. The list of BEST SNPs from case-control analysis at a genome wide level (p-value <1·10-4). From 
now onwards these SNPs will be reported as BEST SNPs. 
2. A list of candidate genes and SNPs historically studied in hypertension or genes selected according 
to their functional role and involvement in biological pathways relevant in hypertension. These 
SNPs were included independently of the association results (i.e independently of the p-value for 
association) and if not already included in the SNP list at point 1. From now onwards these SNPs 
will be reported as candidate SNPs. 
The criteria for SNPs selection are illustrated in the following paragraphs: 
BEST SNPs selection: We selected a list of SNPs significantly associated with hypertension in the case-
control analysis (p-value <1·10-4). Genotyping clusters of these BEST SNPs were checked by visual 
inspection using the Illumina software Genome Studio with the aim to exclude any ambiguous SNP. In 
order to retest and fine map the genes or regions identified in the discovery phase we selected 
further SNPs, neighboring the BEST SNPs, in order to better describe the genetic variability of the 
selected region. For this purpose we referred to the Illumina Gene Annotation of 1M duo and 1M 
quad chips, the densest Illumina chips available, and extracted all the SNPs in the genes mapped by 
the BEST SNPs. We created an "enriched BEST SNP list”of 106,360 SNPs. 
Next steps were: 
Step 1 
From the "enriched BEST SNP list" we excluded all the SNPs mapping more than 100kb upstream and 
downstream the gene start and end. We chose this threshold since 100kb is a reasonable distance in 
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order to include SNPs in possible gene regulatory regions. On coding SNPs and on the original BEST 
SNPs we didn’t apply any of the filters described onwards because we decided to keep them on the 
custom chip. 
Step 2 
We also performed the gene annotation of the "enriched BEST list". With this annotation we found 
that: 
a) Some SNPs had been merged with a new SNP code (the SNP coordinate doesn't change). We 
renamed these SNPs with the new SNP-code that is also recognized by Illumina. 
b) Some SNPs were annotated as triallelic/quadriallelic. These SNPs were removed, since they should 
not be supported by the Illumina Infinium genotyping technology. 
c) Some SNPs did not univocally map in the genome. These SNPs were removed. 
A final "enriched BEST list" was sent to Illumina TechSupport in order to get all validation notes on 
Illumina assay. 
Step 3 
We then selected SNPs according to MAF and p-value of association analysis. 
We chose SNPs with HapMap MAF ≥0.01 in at least one of the three populations of the confirmation 
sample: CEU, CHB and YRI (MAF set). SNPs with no MAF data for any of the 3 populations were 
included anyway. We kept SNPs with a p-value lower than 0.01. SNPs from the 1M quad chip that do 
not have a p-value of association since they were not on the 1M duo chip used in the discovery phase 
were not filtered for p-value of association. 
Step 4 
As a final step we applied a filter on SNPs flanking the original BEST SNP, to reduce the final count. 
The logic behind the flanking filter was to keep one SNP every five, obtaining a final set of 10349 
markers. 
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Candidate SNPs selection 
The following selection steps were followed: 
Step 1: 
Exclusion of all the SNPs mapping more than 100kb upstream or downstream the of the gene. 
Step 2: 
Extraction from Illumina annotation of 1M duo and 1M quad chips of all the SNPs assigned to the 
candidate gene list. 
Step 3: 
We annotated this list and we found that: 
a) Some SNPs had been merged to a new SNP code (the SNP coordinate doesn't change). We 
renamed these SNPs with the new code. 
b) Some SNPs were annotated as triallelic/quadriallelic. These SNPs were removed. 
c) Some SNPs did not univocally map in the genome. These SNPs were removed. 
A final "enriched candidate list" was sent to Illumina TechSupport in order to get all validation notes 
on Illumina assay. 
Step 4: 
We then kept only SNPs with HapMap MAF ≥0.05 in at least one of the three populations of the 
confirmation sample: CEU, CHB and YRI. SNPs with no MAF data for any of the 3 populations were 
included. 
We applied also a filter based on the p-value of association. We removed SNPs having p-value ≥0.01. 
Since this list includes SNPs from the 1M quad that do not have a p-value of association (they were 
not on the chip used in the discovery), we didn't filter out these SNPs. 
Step 5: 
For each candidate gene we included only 5 SNPs and to reach this number we removed one SNP 
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every two. In this way we reduced the number of candidate SNP to 4651 SNPs. 
The list sent to Illumina was comprised of 4651 Candidate SNPs and 10349 BEST SNPs for a total of 
15000 SNPs. 
Due to the fact that during chip manufacturing not all assays passed the Illumina decoding process, 
the real number of SNPs on the custom chip was 14055 (4386 candidate SNPs, 9669 Best SNPs) 
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Supplemental Methods S5: Genotyping and data filtering in the Validation 
Genotyping was performed on 2869 samples by Milan University (UNIMI) and Lausanne University 
(UNIL) who genotyped 1700 and 1169 samples respectively. 
All raw intensity data were collected in UNIMI genotyping centre and analysed with the Illumina 
Software Genome Studio. For custom chips Illumina doesn’t supply the reference cluster file for 
genotype calling we therefore ran training samples to generate a reference cluster file. To create this 
file all SNPs were visually inspected in order to check the accuracy of the cluster plots. Three hundred 
and forty ambiguous SNPs were excluded. 
Genotype calling for the whole sample was performed using the custom reference file. 
In the Validation phase the DNA call rate threshold was set at 0.98 and this led to the exclusion of 173 
DNAs from the final data set that comprised of 2696 DNAs. 
 
Supplemental Methods S6: In-silico genotype data for replication 
We meta-analyzed rs3918226 using in silico data from, ASCOT/AIBIII/NBS, BRIGHT, EPIC Turin, HYPEST 
and NORDIL/MDC studies. 
In particular, ASCOT/AIBIII/NBS, BRIGHT and NORDIL/MDC cohorts were genotyped with Illumina 
Human CVD BeadArray. The HumanCVD BeadChip is the first high-density SNP genotyping standard 
panel specifically targeted for cardiovascular disease (CVD) studies. The BeadChip features 49,452 
markers that capture genetic diversity across approximately 2,100 genes associated with CVD 
processes such as blood pressure changes, insulin resistance, metabolic disorders, dyslipidemia, and 
inflammation.  
HYPEST samples were genotyped using the KASPAr assay at Barts and The London Genome Centre. 
Only SNPs passing quality control thresholds of Hardy-Weinberg equilibrium (p>0.001) and with a call 
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rate >90% were included in the analyses.  
The SNP rs3918226 was genotyped in EPIC Turin cohort by the 5’-Nuclease assay (TaqMan) with a 
fluorogenic Minor Groove Binder probe on ABI-7900 (Applied Biosystems).  
 
Supplemental Methods S7: Quality Control 
All QC steps were performed in accordance with the protocol written by C.A Anderson et al [19] 
The Discovery sample was comprised of 4059 genotyped individuals who underwent a quality control. 
143 Samples having Call Rate <0.95 were excluded. 56 subjects with genotypic sex mismatch 
(difference between the gender reported in clinical data and the one estimated with sex SNPs 
genotyped) were identified and removed from the analysis. 
Using genome-wide IBD estimation (PLINK version 1.7 [20]) we identified and removed from the 
analysis 64 duplicated and 156 related subjects (44 family components, 63 siblings, 23 
parent/offspring, 26 second degree). Using the EIGENSOFT package (version 2.0) [21, 22], we removed 
25 outliers defined as individuals that exceed a default number of standard deviations (6.0) from the 
whole sample. After quality control the final case-control sample comprised of 3615 subjects, 1865 
hypertensive cases, 1750 healthy controls (2,294 males, 1,321 females). 
According ethnicity the HYPERGENES sample is composed by 906 North European subjects (25.06%), 
1399 Sardinians (38.70 %) and 1310 Continental Italy (36.24%). supplemental table S1 shows the 
sample distribution in different cohorts divided between cases-controls and genotyping centres. 
SNPs with a minor allele frequency (MAF) <1%, in significant Hardy-Weinberg disequilibrium (p-
value<1·10-8) and with call rate <99% were removed leaving 882564 SNPs for analysis. We assessed 
population structure within the data using principal components analysis (PCA) as implemented in 
EIGENSTRAT [21, 22] to infer continuous axes of genetic variation. 
After association tests the cluster plots of all SNPs taken forward for validation were manually 
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inspected to check the fidelity of genotype assignment. 
The Validation sample was composed by 2696 genotyped individuals.After data quality control for 
relatedness/duplicates (32 duplicated and 33 related subjects) the final case-control sample was 
composed by 2631 subjects, 1385 hypertensives and 1246 controls (1,417 males and 1,214 females). 
According to ethnicity, the HYPERGENES sample was comprised of 1262 North Europeans (47.97%), 
788 Sardinians (29.95 %) and 581 Continental Italians (22.08%). supplemental table S2 shows the 
sample distribution in different cohorts divided between cases, controls and genotyping centers. 
We filtered out 335 SNPs on the basis of SNP genotype call rates (<99%), 2641 SNPs for Minor Allele 
Frequency (< 0.01) and 39 markers that failed HWE test in controls (p-value <1·10-6). After frequency 
and genotyping pruning, 10684 autosomal SNPs were available for the association analysis. 
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Supplemental Methods S8: Principal Component Analysis 
In the discovery sample, we performed PCA using 1M SNPs using the EIGENSOFT package (version 
2.0) [21, 22]. We removed 25 genetic outliers defined as individuals that exceed 6 standard deviations 
from the whole sample along any of the principal components. 
Results for the first 2 PCs are described in supplemental figure S1. The plot clearly shows subjects 
clustering according to their geographical origin. In supplemental figure S1A the samples are 
represented as macro-groups (North Europe, Continental Italy and Sardinia). Supplemental figure S1B 
shows the same clusters with the individuals marked according to the recruitment centres. 
We selected as significant the first 10 PCs (P-value < 1·10-7) to include them as covariates in the 
logistic regression model. 
In the Validation sample, PCA was carried out using 10684SNPs. We excluded 21 subjects as outliers 
(6 standard deviations from the whole sample). 
The results, for the first 2 PCs, are shown in supplemental figure S3. The distribution of the three 
macro-groups is very similar in the discovery and validation samples. However, due to limited number 
of SNPs, clusters are not as well defined as in the discovery sample. To validate the use of the PCs as 
covariates in logistic regression, we re-run the PCA on the discovery sample using only the common 
SNPs between the two study phases. We could correctly replicate the distribution of the discovery 
subjects in the three macro-areas (data not shown). We used as covariates in association analysis the 
first 10 PCs (P-value < 1·10-2). 
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Supplemental Methods S9: Statistical Analysis 
In the discovery phase, we tested each SNP for association with Hypertension using a logistic 
regression under an additive model with adjustment for sex and for the first 10 PCs, as implemented 
in PLINK [20]. Residual inflation (1.04) of the test statistic was corrected using genomic control. 
In the Validation phase, logistic regression analysis was carried out using an additive genetic model 
adjusted for sex and for the first 10 PCs. 
The basic statistical analyses were performed in accordance with the protocol written by G.M. Clarke 
et Al [23]. 
Combined analysis for HYPERGENES discovery, HYPERGENES Validation, ASCOT/AIBIII/NBS, BRIGHT, 
Epic Turin, HYPEST and NORDIL/MDC results was conducted using both Z-score and inverse variance 
weighting meta-analysis as implemented in METAL [24].  
In the meta-analysis, a genome-wide significance threshold of 5·10–8 was considered as genome-wide 
significant.  
The heterogeneity analysis tests whether observed effect sizes (or test statistics) are homogeneous 
across samples. A test for heterogeneity examines the null hypothesis that all studies are evaluating 
the same effect. The usual test statistic (Cochran's Q) is computed by summing the squared deviations 
of each study's estimate from the overall meta-analytic estimate, weighting each study's contribution 
in the same manner as in the meta-analysis [25,26]. The resulting heterogeneity statistic has n-1 
degrees of freedom for n cohorts.  
In our study, the p value of heterogeneity calculated for HYPERGENES cohorts is 0.13. It decreased 
slightly, but remained non-significant, when also EPIC-Turin was considered together in the meta-
analysis (p=0.092), as expected, since the recruitment criteria for cases and controls were identical. 
Conversely, the heterogeneity significantly increased (p=0.005) when HYPERGENES cohort was meta-
analyzed with all the other cohorts (ASCOT/AIBIII/NBS, BRIGHT, HYPEST and NORDIL/MDC). 
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We tested for interaction between the discovered eNOS SNP (rs3918226) and the most plausible 
interactive partners of the eNOS gene: actin genes (ACTA1, ACTA2, ACTB, ACTG1, ACTG2) and HSP90 
genes (HSP90AA1, HSP90AA2, HSP90AB1). In total 159 SNPs were tested for interaction. Usual 
covariates, sex and ancestry principal components were included in the logistic regression. To assess 
significance, multiple testing corrections were applied. Since many of the SNPs are in high LD with 
each other, we estimated the Per Comparison Error Rate (PCER) which provides a weak control of the 
false discovery rate (FDR) and we permuted the phenotype 500 times [27]. We used a loose 20% false 
discovery rate threshold providing suggestive evidence for interactions. Since the PCER is estimated 
via permutations, dependency between the tests is fully accounted for. 
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Supplemental Figures and tables 
  North Europe Continental Italy Sardinia 
Affection status Hypertensives Normotensives Hypertensives Normotensives Hypertensives Normotensives 
number of individuals  563 343 574 736 728 671 
 Percent women (%) 46.91 53.09 22.3 41.7 32.83 33.08 
age (yrs) 48.3 (8.6) 60.0 (5.0) 45.2 (8.8) 59.5 (6.1) 50.9 (12.4) 62.9 (12.0) 
body mass index (kg/m2) 27.9 (5.2) 26.1 (3.8) 26.4 (3.1) 24.6 (2.9) 27.5 (3.9) 26.0 (3.7) 
SBP (mm Hg) 143.1 (16.9) 119.2 (9.9) 148.7 (8.9) 125.0 (7.0) 158.5 (14.5) 123.9 (9.8) 
SBP after G BP Gen 
adjustment for treatment1 
(mm Hg) 
150.2 (14.4) 119.2 (9.9) 148.8 (8.9) 125.0 (7.0) 158.5 (14.5) 123.9 (9.8) 
DBP (mm Hg) 89.8 (10.5) 74.0 (6.3) 96.4 (6.1) 79.5 (4.6) 102.1 (9.1) 77.1 (6.9) 
DBP after G BP Gen 
adjustment for treatment1 
(mm Hg) 
94.6 (9.0) 74.0 (6.3) 96.5 (6.0) 79.5 (4.6) 102.1 (9.1) 77.1 (6.9) 
Treated for hypertension (%) 46.71 - 1.05 - 0 - 
Supplemental Table S1. Demographic and clinical description of discovery samples into the three macro-areas (North Europe, Continental Italy and 
Sardinia) and divided between cases and controls. The table reports the mean values and, in parenthesis, the standard deviations. 
                                                 
1
 Tobin MD, et al. Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. Stat. Med. 24, 2911–2935 (2005). 
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 North Europe Continental Italy Sardinia 
affection status Hypertensives Normotensives Hypertensives Normotensives Hypertensives Normotensives 
number of individuals  757 505 256 325 372 416 
per cent women (%) 44.78 36.63 19.53 58.46 48.66 64.66 
age (yrs) 46.66 (8.46) 62.89 (6.6) 43.06 (8.39) 62.92 (7.22) 50.18 (10.14) 60.59 (6.15) 
body mass index (kg/m2)  26.20 (4.19) 25.68 (3.75) 26.30 (3.22) 25.21 (3.47) 27.42 (4.31) 25.05 (4.46) 
SBP (mm Hg) 153.38 (19.80) 119.77 (7.68) 149.78 (14.64) 121.81 (7.20) 158.96 (13.84) 123.49 (9.23) 
SBP after G BP Gen 
adjustment for treatment2 
(mm Hg) 
162.22 (20.84) 119.77 (7.68) 152.25 (14.65) 121.81 (7.20) 158.96 (13.84) 123.49 (9.23) 
DBP (mm Hg) 97.20 (12.36) 73.43 (7.15) 96.75 (9.99) 72.47 (6.04) 101.83 (7.96) 75.43 (7.2) 
DBP after G BP Gen 
adjustment for treatment2 
(mm Hg) 
103.10 (12.35) 73.43 (7.15) 98.24 (9.28) 72.47 (6.04) 101.83 (7.96) 75.43 (7.2) 
treated for hypertension (%) 60.50 - 14.84 - 0 - 
Supplemental Table S2. Demographic and clinical description of Validation samples into the three macro-areas (North Europe, Continental Italy 
and Sardinia) and divided between cases and controls. The table reports the mean values and, in parenthesis, the standard deviations. 
                                                 
2
 Tobin MD, et al. Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. Stat. Med. 24, 2911–2935 (2005). 
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  EPOGH-FLEMENGO 
Wandsworth Heart & Stroke Study 
(WHSS)  
number of individuals  1514 306 
 Percent women (%) 52.58 57.19 
age (yrs) 48.04 (6.05) 47.83 (4.8) 
body mass index (kg/m2) 26.60  (3.98) 25.36  (4.32) 
SBP (mm Hg) 125.30 (15.30) 121.32 (14.99) 
SBP after G BP Gen adjustment for treatment1 (mm Hg) 126.59  (16.48) 121.32  (14.99) 
DBP (mm Hg) 78.34 (10.33) 77.52 ( 8.56) 
DBP after G BP Gen adjustment for treatment1 (mm Hg) 79.20 (11.02) 77.52  (8.56 ) 
Treated for hypertension (%) 8.6 0 
Supplemental Table S3. Demographic and clinical description of population based samples (EPOGH-FLEMENGO and WHSS) used for the 
assessment of the quantitative effect of the rs3918226 on BP. 
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Genome wide association results for hypertension-associated SNPs with p-value adjusted for GC < 1E-04  
SNP CHR 
Position 
(bp) 
Location  
Nearest 
gene 
Coded 
Allele 
Non 
coded 
Allele 
MAF OR 
Lower limit, 
CI 95 
Upper limit, 
CI 95 
P 
P adjusted for 
GC 
rs783145 6 161072439 intronic PLG A G 0.50 1.27 1.15 1.40 8.53E-07 1.41E-06 
rs341408 15 58928982 intronic RORA A G 0.38 1.27 1.15 1.40 1.74E-06 2.79E-06 
rs7907270 10 78550949 intronic KCNMA1 G A 0.40 1.27 1.15 1.40 2.35E-06 3.73E-06 
rs783182 6 1.61E+08 intronic PLG A G 0.49 1.25 1.14 1.38 2.95E-06 4.64E-06 
rs4976593 5 1.68E+08 intronic WWC1 G A 0.33 1.27 1.15 1.41 3.75E-06 5.84E-06 
rs1406891 6 1.61E+08 intergenic PLG G A 0.49 1.25 0.73 0.88 3.99E-06 6.20E-06 
rs3918226 7 1.5E+08 intronic NOS3 T C 0.12 1.42 1.22 1.66 4.81E-06 7.42E-06 
rs10519080 15 58925751 intronic RORA G A 0.14 1.37 1.20 1.57 5.79E-06 8.87E-06 
rs11686131 2 27362214 intronic TRIM54 G A 0.18 1.34 0.66 0.85 5.93E-06 9.08E-06 
rs1084656 6 1.61E+08 intergenic PLG C A 0.50 1.24 1.13 1.37 6.67E-06 1.02E-05 
rs4665962 2 27368609 intronic TRIM54 A G 0.18 1.33 0.66 0.85 7.09E-06 1.08E-05 
rs631208 16 9307225 intergenic LOC653737 A G 0.41 1.25 0.72 0.88 8.09E-06 1.22E-05 
rs1975384 2 27395545 intronic MPV17 G A 0.18 1.33 0.66 0.85 8.15E-06 1.23E-05 
rs1247558 6 1.61E+08 intergenic PLG G A 0.50 1.24 1.13 1.36 8.30E-06 1.26E-05 
rs783165 6 1.61E+08 intergenic PLG C A 0.50 1.24 1.13 1.36 9.73E-06 1.46E-05 
rs1621801 6 1.61E+08 intergenic PLG C A 0.49 1.24 0.73 0.89 1.10E-05 1.64E-05 
GA006079 6 1.61E+08 intergenic PLG C G 0.50 1.24 1.13 1.36 1.12E-05 1.67E-05 
rs6555802 5 1.68E+08 intronic WWC1 A C 0.34 1.25 1.13 1.38 1.13E-05 1.69E-05 
rs1992291 2 27357816 intergenic DNAJC5G A G 0.20 1.31 0.68 0.86 1.38E-05 2.04E-05 
rs2366947 2 85941520 intronic ST3GAL5 A G 0.34 1.25 0.73 0.89 1.54E-05 2.27E-05 
rs2565721 6 1.61E+08 intergenic PLG G A 0.48 1.23 0.74 0.89 1.71E-05 2.51E-05 
rs6721125 2 85958240 intronic ST3GAL5 G A 0.35 1.25 0.73 0.89 1.71E-05 2.52E-05 
rs6753350 2 85959009 intronic ST3GAL5 A G 0.35 1.25 0.73 0.89 1.78E-05 2.61E-05 
rs895314 5 13900984 intronic DNAH5 G A 0.17 1.32 0.67 0.86 1.83E-05 2.69E-05 
rs1511789 15 52442052 intronic UNC13C A G 0.29 1.26 1.13 1.40 1.88E-05 2.76E-05 
rs11787445 8 1.35E+08 intergenic LOC729395 A G 0.24 1.28 1.14 1.43 1.89E-05 2.77E-05 
rs2023843 7 27209746 intergenic HOXA13 A G 0.06 1.58 0.51 0.78 2.01E-05 2.94E-05 
rs4665960 2 27321102 intergenic CAD G A 0.22 1.29 0.69 0.87 2.03E-05 2.97E-05 
rs2930120 12 66600079 intergenic LOC341333 A G 0.25 1.27 1.14 1.41 2.03E-05 2.97E-05 
rs7733887 5 1.69E+08 intergenic SLIT3 G A 0.10 1.42 1.21 1.68 2.13E-05 3.10E-05 
rs929250 7 27211626 intergenic HOXA13 A C 0.06 1.58 0.51 0.78 2.13E-05 3.11E-05 
rs1561535 2 27324529 intergenic CAD G A 0.28 1.26 0.71 0.88 2.18E-05 3.18E-05 
rs1122227 2 27397789 intronic MPV17 G A 0.18 1.31 0.67 0.86 2.32E-05 3.37E-05 
rs783156 6 1.61E+08 intergenic PLG G A 0.49 1.23 0.74 0.90 2.37E-05 3.44E-05 
rs7209417 17 72877103 intronic SEPT9 G A 0.37 1.24 0.73 0.89 2.42E-05 3.51E-05 
rs4553826 2 85948712 intronic ST3GAL5 G A 0.35 1.24 0.73 0.89 2.44E-05 3.54E-05 
rs2580761 2 27279866 intronic SLC5A6 G A 0.22 1.29 0.69 0.87 2.60E-05 3.76E-05 
rs2908764 12 66598283 intergenic LOC341333 A G 0.25 1.26 1.13 1.40 2.79E-05 4.03E-05 
rs4962095 9 1.35E+08 intronic GBGT1 C A 0.47 1.23 1.12 1.35 2.89E-05 4.16E-05 
rs2073927 9 1.35E+08 intronic GBGT1 A G 0.47 1.23 1.12 1.35 2.90E-05 4.18E-05 
rs501630 11 65393849 intronic EFEMP2 A G 0.43 1.23 1.12 1.35 2.93E-05 4.22E-05 
rs2160243 12 66602263 intergenic LOC341333 G A 0.25 1.26 1.13 1.40 3.00E-05 4.31E-05 
rs4722675 7 27210487 intergenic HOXA13 G A 0.06 1.56 0.52 0.79 3.20E-05 4.59E-05 
rs9653564 2 27326122 intergenic SLC30A3 G A 0.23 1.27 0.70 0.88 3.26E-05 4.67E-05 
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Genome wide association results for hypertension-associated SNPs with p-value adjusted for GC < 1E-04  
SNP CHR 
Position 
(bp) 
Location  
Nearest 
gene 
Coded 
Allele 
Non 
coded 
Allele 
MAF OR 
Lower limit, 
CI 95 
Upper limit, 
CI 95 
P 
P adjusted for 
GC 
rs7276718 21 19329160 intergenic PPIAL3 G A 0.45 1.23 1.11 1.35 3.36E-05 4.82E-05 
rs13404446 2 27372758 intronic TRIM54 G A 0.24 1.27 0.70 0.88 3.39E-05 4.86E-05 
rs3735533 7 27212418 intergenic HOXA13 G A 0.06 1.56 0.52 0.79 3.49E-05 5.00E-05 
rs7658173 4 89401542 intergenic PPM1K A G 0.37 1.23 1.12 1.36 3.54E-05 5.06E-05 
rs7808249 7 86821651 intronic CROT A G 0.26 1.26 1.13 1.40 3.68E-05 5.25E-05 
rs11126918 2 27292214 intronic C2orf28 G A 0.22 1.28 0.70 0.88 3.70E-05 5.28E-05 
rs7223756 17 74794846 intronic HRNBP3 G A 0.47 1.22 1.11 1.35 3.89E-05 5.54E-05 
rs1659685 2 27274194 intergenic SLC5A6 A G 0.29 1.25 0.72 0.89 4.08E-05 5.80E-05 
rs1563447 17 74805025 intronic HRNBP3 G A 0.30 1.24 0.73 0.89 4.13E-05 5.88E-05 
rs4665376 2 27362536 intronic TRIM54 A G 0.24 1.26 0.71 0.88 4.15E-05 5.90E-05 
rs1640235 7 5609157 intronic FSCN1 A G 0.09 1.44 1.21 1.71 4.19E-05 5.96E-05 
rs6880706 5 1.18E+08 intergenic DTWD2 G A 0.47 1.22 1.11 1.35 4.31E-05 6.12E-05 
rs13404327 2 27372657 intronic TRIM54 C A 0.24 1.26 0.71 0.89 4.43E-05 6.28E-05 
rs563881 15 52449942 intronic UNC13C A G 0.29 1.25 1.12 1.38 4.52E-05 6.40E-05 
rs4665963 2 27382196 intronic TRIM54 A G 0.25 1.26 0.71 0.89 4.73E-05 6.69E-05 
rs10858918 12 88620476 intergenic LOC338758 G A 0.37 1.23 0.73 0.90 4.74E-05 6.71E-05 
rs7575245 2 27380825 intronic TRIM54 G A 0.24 1.26 0.71 0.89 4.75E-05 6.72E-05 
rs10264581 7 27221942 intergenic HOXA13 A G 0.04 1.65 0.48 0.77 4.85E-05 6.86E-05 
rs4789997 17 74799181 intronic HRNBP3 A G 0.34 1.23 0.74 0.90 4.87E-05 6.88E-05 
rs9849845 3 1.09E+08 intergenic BBX A C 0.49 1.22 0.75 0.90 4.92E-05 6.94E-05 
rs813641 6 1.61E+08 intronic PLG A G 0.15 1.32 1.15 1.51 5.05E-05 7.13E-05 
rs1533605 2 85945764 intronic ST3GAL5 A G 0.35 1.23 0.73 0.90 5.16E-05 7.28E-05 
rs1517331 2 1.69E+08 intronic STK39 G A 0.13 1.35 1.17 1.55 5.36E-05 7.55E-05 
rs7751252 6 79019345 intergenic IRAK1BP1 G A 0.08 1.44 1.21 1.72 5.49E-05 7.73E-05 
rs4665965 2 27389884 intronic MPV17 A G 0.24 1.26 0.71 0.89 5.68E-05 7.98E-05 
rs9888336 12 1.32E+08 5UTR ZNF26 A G 0.03 1.82 1.36 2.44 6.03E-05 8.45E-05 
rs1993643 10 1.07E+08 intergenic SORCS3 A G 0.31 1.24 1.12 1.37 6.14E-05 8.60E-05 
rs3769143 2 27304228 intronic CAD G A 0.29 1.24 0.72 0.90 6.20E-05 8.68E-05 
rs529565 9 1.35E+08 intronic ABO A G 0.32 1.23 0.73 0.90 6.25E-05 8.75E-05 
rs1401283 2 1.71E+08 intronic MYO3B G A 0.38 1.23 0.74 0.90 6.26E-05 8.76E-05 
rs1275522 2 27280382 intronic SLC5A6 A G 0.29 1.24 0.72 0.90 6.33E-05 8.85E-05 
rs11996335 8 77536681 intergenic ZFHX4 G A 0.49 1.22 1.10 1.34 6.33E-05 8.86E-05 
rs2847579 18 46616662 intergenic MRO C A 0.41 1.22 1.11 1.34 6.34E-05 8.87E-05 
rs7221079 17 72856622 intronic SEPT9 A G 0.35 1.23 0.73 0.90 6.48E-05 9.06E-05 
rs13241373 7 5789747 intergenic RNF216 A G 0.10 1.40 1.19 1.66 6.58E-05 9.19E-05 
rs608270 12 1.32E+08 intronic ZNF84 A G 0.03 1.84 1.36 2.49 6.62E-05 9.25E-05 
rs601679 12 1.32E+08 3UTR ZNF84 A G 0.03 1.84 1.36 2.49 6.62E-05 9.25E-05 
rs11655079 17 72860270 intronic SEPT9 G A 0.35 1.23 0.74 0.90 6.65E-05 9.29E-05 
rs7794193 7 27261226 intergenic EVX1 G A 0.04 1.66 0.47 0.77 6.71E-05 9.37E-05 
rs4680062 3 1.55E+08 intergenic LOC152118 A G 0.14 1.33 1.16 1.53 6.72E-05 9.38E-05 
rs11147244 12 1.32E+08 intergenic ZNF10 G A 0.03 1.85 1.37 2.51 6.83E-05 9.53E-05 
rs1275501 2 27272786 intergenic SLC5A6 C A 0.29 1.24 0.72 0.90 6.92E-05 9.65E-05 
rs4722670 7 27196074 intergenic HOXA11S A G 0.08 1.44 0.58 0.83 6.93E-05 9.67E-05 
rs11608 2 27288878 5UTR C2orf28 A G 0.29 1.24 0.73 0.90 7.01E-05 9.77E-05 
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Genome wide association results for hypertension-associated SNPs with p-value adjusted for GC < 1E-04  
SNP CHR 
Position 
(bp) 
Location  
Nearest 
gene 
Coded 
Allele 
Non 
coded 
Allele 
MAF OR 
Lower limit, 
CI 95 
Upper limit, 
CI 95 
P 
P adjusted for 
GC 
rs573740 15 52470723 intronic UNC13C A G 0.30 1.24 1.11 1.37 7.10E-05 9.90E-05 
rs623100 12 1.32E+08 coding ZNF84 A C 0.03 1.84 1.36 2.48 7.12E-05 9.92E-05 
 
Supplemental Table S4: List of Best discovery results (p-value adjusted for Genomic Control< 10-4).  
To retrieve information about SNPs and their genomic context (the nearest gene) we used the hg18 
(NCBI 36) assembly.  
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SNP  
Alleles 
(coded/other) 
CHR GENE LOCATION 
DISTANCE 
 TO GENE 
STUDY  
(SAMPLE) 
OR P VALUE 
OR 
HYPERGENES 
P 
HYPERGENES 
OR 
COMBINED 
P 
COMBINED 
rs2681472 A/G 12 ATP2B1 Intronic -1620 
Levy et Al 
28
 
 (CHARGE) 
1.17 1.65E-08 1.14 4.00E-02 1.16 1.89E-09 
rs11105354 G/A 12  ATP2B1 Intronic -2032 
Levy et Al 
28 
(CHARGE) 
0.85 1.80E-08 0.88 3.79E-02 0.86 1.97E-09 
rs2681492 G/A 12 ATP2B1 Intronic -687 
Levy et Al 
28 
(CHARGE) 
0.87 8.40E-08 0.88 4.04E-02 0.87 9.76E-09 
rs11105328 G/A 12 WDR51B intergenic -22613 
Levy et Al 
28
 
(CHARGE) 
0.86 7.10E-07 0.90 8.74E-02 0.87 1.56E-07 
rs653178 A/G 12 ATXN2 Intronic -14033 
Newton-Cheh et Al 
29
 
(Global Bpgen) 
0.93 7.00E-07 0.87 2.81E-03 0.93 1.69E-08 
rs17367504 A/G 1 MTHFR Intronic -160 
Newton-Cheh et Al 
29 
(Global Bpgen) 
0.89 2.00E-09 0.89 1.39E-01 0.89 7.19E-10 
rs1378942 C/A 15 CSK intronic -2306 
Newton-Cheh et Al
 29
 
(Global Bpgen) 
1.1 2.00E-14 1.03 5.60E-01 1.06 8.80E-14 
rs13333226 G/A 16 UROMOD intergenic -1617 Padmanabhan et Al
30
 0.85 1.50E-13 0.84 8.72E-03 0.85 4.88E-15 
 
Supplemental Table S5: meta-analysis of top SNPs previously published in literature as associated with Hypertension in Genome-wide 
association studies and HYPERGENES results. 
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rsSNP1-allele Gene1 rsSNP2-allele Gene2 Interaction effect size 
Interaction p-value 
(20% FDR) 
rs13447427-G ACTB rs3918226-T NOS3 0.47 1.34E-03 
rs7503750-G ACTG1 rs3918226-T NOS3 -0.42 1.57E-03 
rs4922796-G HSP90AA2 rs3918226-T NOS3 -0.36 3.47E-03 
rs17309979-G HSP90AA2 rs3918226-T NOS3 0.35 4.88E-03 
 
Supplemental Table S6: Interaction analysis of ACTB (Beta Actin), ACTG1 (Gamma 1 Actin) and HSP90AA2 (heat shock protein 90kDa alpha 
(cytosolic) with eNOS. 
Interacting alleles, effects size and P-values are reported. The reported SNPs were selected, controlling the False discovery Rate at 20%. 
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A. 
SBP 
rs3918226 Mean Std. Dev. Freq. 
    
GG 125.4 16.2 1523 
GT 126.7 16.7 276 
TT 131.9 19.2 21 
        
Total 125.7 16.4 1820 
 
 
B. 
DBP 
    
rs3918226 Mean Std. Dev. Freq. 
    
GG 78.7 10.6 1523 
GT 79.6 10.7 276 
TT 85.3 12.6 21 
        
Total 78.9 10.7 1820 
 
Supplemental Table S7: BP distribution according to rs3918226 genotype.  
The table reports the mean values, the standard deviations and the frequencies of 
SBP (A) and DBP (B) for each genotype. In the linear regression analysis, accounting 
for sex, bmi, age and age2, we obtained a  coefficient of 1.91 (95% CI 0.16-3.66, p-
value= 0.032) for SBP (A) and of 1.40 (95% CI 0.25-2.55, p-value=0.017) for DBP (B), 
respectively.  
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Supplemental Figures Legend 
Figure S1 Principal component plot of discovery sample. A. Samples are represented as 
macro-groups: North Europe in blue, Continental Italy in green and Sardinia in 
purple. B: Samples are marked according to the recruitment centres.  
Figure S2 Manhattan plot of single SNP logistic regression test statistics, adjusted for 
gender and PCs, in discovery GWA analysis. Results are reported as –log10 (P-
value) by genomic position.  
Figure S3 Principal component plot of Validation sample. Samples are represented as 
macro-groups: North Europe in blue, Continental Italy in green and Sardinia in 
purple.  
Figure S4 Q-Q plot of combined analysis. 
Figure S5 Forest plot of meta-analysis between discovery samples and Validation sub-
samples. The Validation sample is divided in Sardinia, Continental Italy, EPOGH, 
Progress with Victorian Family Heart Study cohort and France subgroups. The 
squares and the horizontal lines correspond to the OR and 95% CI, and the 
diamond represents the combined OR and 95% CI. The test of heterogeneity was 
applied (I-squared and p-value). 
Figure S6 Conservation of eNOS3 region. Measure of evolutionary conservation in Primate 
and Placental Mammals using the conservation track of UCSC genome browser. 
The red line represents the position of rs3918226. The black rectangles 
underneath indicate that the locus is conserved along the different species 
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Supplemental Figure S1. Principal component plot of discovery sample. A. Samples are 
represented as macro-groups: North Europe in blue, Continental Italy in green and Sardinia 
in purple. B: Samples are marked according to the recruitment centres.  
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Supplemental Figure S2. Manhattan plot of single SNP logistic regression test statistics, 
adjusted for gender and PCs, in discovery GWA analysis. Results are reported as –log10 (P-
value) by genomic position.  
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Supplemental Figure S3. Principal component plot of Validation sample. Samples are 
represented as macro-groups: North Europe in blue, Continental Italy in green and Sardinia 
in purple.  
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Supplemental Figure S4: Q-Q plot of combined analysis. 
40 
 
 
 
 
Supplemental Figure S5: Forest plot of meta-analysis between discovery samples and 
Validation sub-samples. The Validation sample is divided in Sardinia, Continental Italy, 
EPOGH, Progress with Victorian Family Heart Study cohort and France subgroups. The 
squares and the horizontal lines correspond to the OR and 95% CI, and the diamond 
represents the combined OR and 95% CI. The test of heterogeneity was applied (I-squared 
and p-value). 
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Supplemental Figure S6: Conservation of eNOS3 region. Measure of evolutionary 
conservation in Primate and Placental Mammals using the conservation track of 
UCSC genome browser. The red line represents the position of rs3918226. The black 
rectangles underneath indicate that the locus is conserved along the different 
species.
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